Mirion Technologies Inc
NYSE:MIR

Watchlist Manager
Mirion Technologies Inc Logo
Mirion Technologies Inc
NYSE:MIR
Watchlist
Price: 23.83 USD 1.75% Market Closed
Market Cap: 6B USD

Mirion Technologies Inc
Investor Relations

Mirion Technologies Inc., a relatively unheralded but vital player in the world of radiation measurement and detection, provides critical solutions across a variety of sectors, from medical imaging to safety and environmental monitoring. The company operates predominantly in two key segments: Medical and Industrial. In the medical realm, Mirion offers radiation therapy quality assurance products and software that are essential for ensuring the efficacy and safety of radiation used in cancer treatments. By integrating advanced software with precision hardware, it plays a pivotal role in the oncology landscape, ensuring that hospitals and clinics can deliver safe and effective radiation therapy. This focus on precision and safety in healthcare drives significant revenues as healthcare providers rely on these technologies to keep patient outcomes at the forefront.

Beyond healthcare, Mirion extends its expertise into the industrial sector, providing technology for nuclear power facilities, military applications, and laboratories. Their sophisticated detection devices are employed not just for energy generation but also for ensuring compliance with safety standards and regulations across diverse industries. Alongside, Mirion’s environmental solutions help in monitoring and managing radiation levels in various settings, supporting governmental and industrial efforts to safeguard people and the environment. By continuously innovating and developing tailor-made solutions that cater to the stringent requirements of radiation measurement and detection, Mirion secures its position as a key supplier in industries where precision and reliability are non-negotiable, thus underpinning its revenue streams and business model.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 29, 2025
AI Summary
Q3 2025

Revenue Growth: Mirion reported third quarter revenue of $223 million, up nearly 8% year-over-year, driven mainly by strong performance in the nuclear power end market.

Margin Expansion: Adjusted EBITDA grew 14.7% to $52.4 million, with both the Nuclear & Safety and Medical segments contributing to improved margins.

Free Cash Flow Guidance Raised: The company increased the low end of its 2025 adjusted free cash flow guidance to $100–115 million and expects EBITDA conversion between 45–49%.

Nuclear Power Momentum: Orders in the nuclear power end market grew 21% in Q3, excluding FX, with significant growth in small modular reactor (SMR) orders.

M&A Activity: Mirion is set to broaden its nuclear portfolio through the acquisitions of Paragon Energy Solutions and Certrec, expected to close by year-end.

Medical Segment Performance: Medical segment revenue rose 5.9%, led by strong dosimetry services growth, despite temporary pressure in the U.S. RTQA business.

Large Project Pipeline: $65 million in large project awards were already booked or awarded by October, with $285 million still in the opportunity pipeline.

Key Financials
Revenue
$223 million
Organic Revenue Growth (Company-wide)
4.7%
Nuclear Power End Market Organic Revenue Growth
9%
Year-to-date Nuclear Power End Market Organic Revenue Growth
11%
Adjusted EBITDA
$52.4 million
Adjusted Free Cash Flow
$18 million (Q3), $53 million (YTD)
Adjusted Orders (Q3)
2.4% growth
Nuclear Power End Market Orders (Q3)
21% growth (16% ex-FX)
SMR-related Orders (Q3)
$17 million
SMR-related Orders (YTD)
$26 million
Adjusted EPS
$0.12 per share
Nuclear and Safety Segment Revenue
$144.6 million
Nuclear and Safety Segment Organic Revenue Growth
4.4%
Nuclear and Safety Segment Adjusted EBITDA
$40.6 million
Nuclear and Safety Segment Adjusted EBITDA Margin
28.1%
Medical Segment Revenue
$78.5 million
Medical Segment Organic Revenue Growth
5.2%
Medical Segment Adjusted EBITDA
$28.2 million
Medical Segment Adjusted EBITDA Margin
35.9%
Blended Cost of Debt (expected year-end 2025)
2.8%
Earnings Call Recording
Other Earnings Calls

Management

Mr. Loic Eloy
Group President of Technologies
No Bio Available
Mr. Christopher Moore CPA
Chief Accounting Officer & Principal Accounting Officer
No Bio Available
Ms. Emmanuelle Lee J.D.
Chief Legal Officer, Chief Compliance Officer & Secretary
No Bio Available
Ms. Erin Schesny
Chief Marketing Officer
No Bio Available
Ms. Alison Ulrich
Chief Human Resources Officer
No Bio Available
Ms. Shelia Webb
Chief Digital Officer
No Bio Available
Mr. Mark Siviter
Chief Revenue Officer
No Bio Available

Contacts

Address
GEORGIA
Atlanta
1218 Menlo Drive
Contacts
+17704322744.0
www.mirion.com